Pharnext SA announced a financing agreement with returning investor Neovacs S.A. for the issue of 210,938 bonds at a price of €100 per bond for gross proceeds of €21,093,800 on September 30, 2022. The company will also issue share warrants in the transaction. The funding will be done in several tranches. As a part of the transaction, Neovacs S.A. will take a board seat in the company.


On the same date, the company issued 107,000 bonds for gross proceeds of 10,700,000 million in its first tranche. The remaining funding is done in ten additional tranches, including two tranches of a net amount of €2.5 million, respectively, in October and November 2022, then of €1 million net, respectively, in December 2022 and January 2023, and finally of €500,000 net per month from February 2023 to July 2023 inclusive.